143D, a novel selective KRASG12C inhibitor exhibits potent antitumor activity in preclinical models.

Abstract excerpt

The KRASG12C mutant has emerged as an important therapeutic target in recent years. Covalent inhibitors have shown promising antitumor activity against KRASG12C-mutant cancers in the clinic. In this study, a structure-based and focused chemical library analysis was performed, which led to the identification of 143D as a novel, highly potent and selective KRASG12C inhibitor. The antitumor efficacy of 143D in vitro...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cell Line, Tumor
• Share to Mice